The US contract research organisation (CRO) has installed a Heidelberg Spectralis optical coherence tomography (OCT) unit at the lab.
The firm cited sponsor demand for detailed digital images of the retina that enable precise monitoring of the efficacy and toxicity of drugs and medical devices as the reason for the investment.
Glenwood Glum, Absorption’s director of preclinical studies, said: “This OCT technology gives a huge boost to our ocular testing capabilities, which will immediately benefit our rapidly expanding client base.”
CEO Patrick Dentinger set the new platform in a wider business context, suggesting the firm’s ambition of being the market leader in this type of niche testing “requires scientific expertise, state-of-the-art equipment and facilities, and access to emerging technologies.
“These factors, combined with Absorption Systems’ customer-centric approach, make our commitment to being a top-tier ocular service provider a reality in 2012.”
The expansion is a continuation of the programme Absorption Systems has implemented of the last few years, beginning in 2009 when it set up a new surgical unit for preclinical testing of medical devices.
The new ocular testing unit will provide in vivo pharmacokinetics, efficacy, and safety testing in multiple animal species, as well as in vitro ocular permeability and metabolism analysis using a variety of bespoke models.
This includes ‘human corneal orb’ which is an in vitro permeability model cultured from human pluripotent stem cells, which was developed by Lifeline Cell Technology.